Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part II)

Published: 13-Nov-2026
Regulatory Digital

How the enterprise trap is set: familiar platforms, borrowed requirements and hidden validation costs can turn seemingly safe purchasing decisions into costly operational burdens

You need to be a subscriber to read this article.
Click here to find out more.
Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part II)

If the fit is so often wrong, why do growing manufacturers keep choosing platforms designed for the world's largest healthcare companies?

The decision usually comes from a series of reasonable-sounding choices.

“Industry standard” and “best practice” are largely defined by the organisations that spend the most on their quality management technology.

Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part II)

Requirement documents are adapted from templates written for global enterprises, so they accumulate capabilities that few mid-sized manufacturers will ever use.

Consultants may recommend solutions they have implemented previously; vendors position their top-tier offering as the safe choice and, at some point, someone asks why the company doesn't deploy the technology they used in another, larger company.

Oversized technology carries a cost that goes beyond licence fees: validation. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • IQVIA
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Digital
Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part I)

Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part I)

Read more
As the UK builds its own standalone device framework alongside continuing EU obligations, Mike King argues that manufacturers need quality management technology built for flexibility … not for the scale of the industry's largest players

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Validating AI in pharmaceutical manufacturing: innovation without compromising compliance With artificial intelligence (AI) moving from experimentation into regulated environments, pharmaceutical manufacturers must rethink how they demonstrate software reliability, manage risk and maintain a validated state
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Embracing healthcare innovation with 2D codes Pharmaceutical manufacturers already serialise medicines using 2D codes to meet regulatory requirements, but a 2D code can be so much more than a tick box for compliance, explains Ian Chapman, Strategic Manager for Digital Coding at Domino Printing Sciences
  3. ECJ upholds silanamine STOT RE 2 classification following Evonik appeal The European Court of Justice has dismissed Evonik's challenge to the EU's classification of surface-treated synthetic amorphous silica, confirming the acceptability of read-across as part of chemical hazard assessments
  4. Pace Life Sciences completes EMA GMP inspection at New Jersey CDMO facility The inspection supports renewal of the EU GMP certificate at the company's New Jersey site, which provides pharmaceutical analytical testing, microbiology and development services
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    A completed reply is not a finalised case: how to test AI intake in pharma A medical information response marked complete says nothing about safety information that arrives later. Before accepting an AI intake demonstration, ask to see what happens to the next message: who assesses it, what stays pending and which dates are preserved

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Digital
Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part I)

Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part I)

As the UK builds its own standalone device framework alongside continuing EU obligations, Mike King argues that manufacturers need quality management technology built for flexibility … not for the scale of the industry's largest players
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
The cost of complexity: why mid-tier manufacturers need to rethink regulatory technology strategy (part II)

The cost of complexity: why mid-tier manufacturers need to rethink regulatory technology strategy (part II)

Mid-tier manufacturers can avoid over-engineering by questioning scale, users and integrations, then prioritising built-in GMP workflows, integrated platforms and industry expertise, freeing budget to invest in future capabilities
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
The cost of complexity: why mid-tier manufacturers need to rethink regulatory technology strategy (part I)

The cost of complexity: why mid-tier manufacturers need to rethink regulatory technology strategy (part I)

With the right questions and scrutiny during procurement, organisations can avoid the over-engineering trap and select a QMS solution that fits their requirements and allows them to remain competitive
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Quality management during manufacturing changes: part I

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Regulatory

Merck and Quintiles sign innovative clinical development partnership

Unique strategic collaboration for development and clinical trial execution
Regulatory

Quintiles invests a further US$14m in China

Will also expand lab testing capabilities with SCRC
Regulatory

Quintiles launches Kun Tuo CRO in China

Will develop customised solutions to assist registration of new medicines in China
Subscribe now